Biological relationship event extraction system and method for processing biological information
    2.
    发明申请
    Biological relationship event extraction system and method for processing biological information 审中-公开
    生物关系事件提取系统和处理生物信息的方法

    公开(公告)号:US20060136147A1

    公开(公告)日:2006-06-22

    申请号:US11304030

    申请日:2005-12-15

    IPC分类号: G01N33/48

    CPC分类号: G16B50/00

    摘要: A biological relationship extraction system including a biological named entity substitution unit substituting a biological named entity in a biological document with a predetermined substitution name; a structure analyzing unit parsing the biological named entity in the biological document containing the substituted biological named entity; a relationship analyzing unit analyzing a relationship between biological named entities from the biological literature parsed by the structure analyzing unit and selecting relationship candidates; a relationship determining unit determining whether the relationship candidates delivered from the relationship analyzing unit are biologically meaningful and determining a relationship between biological named entities; and a biological named entity assignment storage unit storing the biological named entity and a substitution name corresponding to the biological named entity and providing a substitution name or a biological named entity.

    摘要翻译: 一种生物关系提取系统,其包括用具有预定取代名称的生物文献中的生物命名实体取代生物命名实体取代单元; 解析包含取代的生物命名实体的生物文件中的生物命名实体的结构分析单元; 关系分析单元,从结构分析单元解析的生物学文献中分析生物命名实体之间的关系,并选择关系候选; 关系确定单元,确定从关系分析单元传递的关系候选是否具有生物学意义,并确定生物命名实体之间的关系; 以及生物命名实体分配存储单元,其存储生物命名实体和与生物命名实体相对应的替代名称,并提供替代名称或生物命名实体。

    Inhibitor of hepatitis B virus replication
    3.
    发明授权
    Inhibitor of hepatitis B virus replication 失效
    乙型肝炎病毒复制抑制剂

    公开(公告)号:US5635473A

    公开(公告)日:1997-06-03

    申请号:US347343

    申请日:1995-04-24

    CPC分类号: C07K14/4746 A61K38/00

    摘要: The present invention relates to a novel use of a biologically active protein, p53 as an inhibitor of hepatitis B virus(HBV) replication. The inhibitory role of p53 on HBV replication was assessed by the reduced levels of three different markers, i.e., HBsAg and HBc/eAg secreted into the medium, HBV DNA, and RNAs. Based on the above results, it was concluded that wild-type p53 specifically represses the activity of pregenomic/core promoter of HBV and inhibits the replication of HBV by down-regulation of the pregenomic/core promoter. Therefore, the present invention provides a novel use of protein p53 as a HBV replication inhibitor which can be developed into an agent for the treatment of acute/chronic hapatitis and prevention of liver cirrhosis and hepatocellular carcinoma(HCC) caused by HBV.

    摘要翻译: PCT No.PCT / KR94 / 00136 Sec。 371日期1995年04月24日 102(e)日期1995年4月24日PCT 1994年10月12日PCT PCT。 公开号WO96 / 11017 日期1996年04月18日本发明涉及生物活性蛋白质p53作为乙型肝炎病毒(HBV)复制抑制剂的新用途。 通过三种不同标志物的水平降低,即分泌到培养基中的HBsAg和HBc / eAg,HBV DNA和RNA来评估p53对HBV复制的抑制作用。 基于上述结果,得出结论,野生型p53特异性抑制HBV的前基因组/核心启动子的活性,并通过下调前基因组/核心启动子来抑制HBV的复制。 因此,本发明提供蛋白质p53作为HBV复制抑制剂的新用途,其可以发展成用于治疗急性/慢性单性疱疹的药物和由HBV引起的肝硬化和肝细胞癌(HCC)的预防。